Monopar Therapeutics
NORTHBROOK, IL · Founded 2014 · CIK 0001645469 · Biotech · Private
Targeted small-molecule therapeutics for Wilson Disease and cancer
monopartx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $2.1M
- 4 Form D · Aug 2017
- 110 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 2 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,105,100 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $4,500,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1377 | Vcreate, Inc. | — | — |
| 1378 | YASO THERAPEUTICS INCORPORATED | — | — |
| 1379 | CHIMERNA THERAPEUTICS, INC. | — | — |
| 1380 | Monopar Therapeutics | — | $2.1M |
| 1381 | INFLAMED, INC. | — | — |
| 1382 | XPOSE THERAPEUTICS, INC. | — | — |
| 1383 | REJUVENATION TECHNOLOGIES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Raymond AndersonDirector
- Michael BrownDirector
- Andrew MazarDirector · Executive Officer
- Chandler RobinsonDirector · Executive Officer · Promoter
- Christopher StarrDirector · Executive Officer
Patents
- Materials And Methods For Treating Coronavirusapplication
- Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceuticalapplication
- Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Useapplication
- Clonidine And/or Clonidine Derivatives For Use In The Prevention Of Skin Injury Resulting From Radiotherapygranted
- 3'-DEAMINO-3'-(2"-PYRROLINE-1"-YL)-5-IMINO-13-DEOXYANTHRACYCLINES And Methods Of Preparationgranted
- Trivalent Radioisotope Bio-targeted Radiopharmaceutical, Methods Of Preparation And Useapplication
- Antibody Radioisotope Constructsapplication
- Urokinase Plasminogen Activator Receptor-targeted Radiopharmaceuticalapplication
- Precision Radioimmunotherapeutic Targeting Of The Urokinase Plasminogen Activartor Receptor (upar) For Treatment Of Severe COVID-19 Diseaseapplication
- Precision Radioimmunotherapeutic Targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for Treatment of Severe COVID-19 Diseaseapplication
- 3'DEAMINO-3'-(2'-PYRROLINE-1"YL)-5-IMINO-13-DEOXYANTHRACYCLINES And Methods Of Preparationapplication
- Squaramide Bi-Functional Chelators and Associated Radiopharmaceuticals and Methods of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.